| 1 |
35013156 | Pediatric multicellular tumor spheroid models illustrate a therapeutic potential by combining BH3 mimetics with Natural Killer (NK) cell-based immunotherapy. | 2022 Jan 10 |
1 |
| 2 |
35074525 | Targeting entry into mitochondria for increased anticancer efficacy of BCL-XL-selective inhibitors in lung cancer. | 2022 Mar |
1 |
| 3 |
35201512 | Dual inhibition of anti-apoptotic proteins BCL-XL and MCL-1 enhances cytotoxicity of Nasopharyngeal carcinoma cells. | 2022 Feb 3 |
2 |
| 4 |
35421634 | BAK plays a key role in A-1331852-induced apoptosis in senescent chondrocytes. | 2022 Jun 18 |
2 |
| 5 |
34100903 | BCL-XL antagonism selectively reduces neutrophil life span within inflamed tissues without causing neutropenia. | 2021 Jun 8 |
1 |
| 6 |
31772331 | Potent efficacy of MCL-1 inhibitor-based therapies in preclinical models of mantle cell lymphoma. | 2020 Feb |
1 |
| 7 |
32346617 | Co-inhibition of BCL-XL and MCL-1 with selective BCL-2 family inhibitors enhances cytotoxicity of cervical cancer cell lines. | 2020 Jul |
2 |
| 8 |
33017468 | BCL-XL inhibition by BH3-mimetic drugs induces apoptosis in models of Epstein-Barr virus-associated T/NK-cell lymphoma. | 2020 Oct 13 |
1 |
| 9 |
33062160 | Discovery of A-1331852, a First-in-Class, Potent, and Orally-Bioavailable BCL-XL Inhibitor. | 2020 Oct 8 |
2 |
| 10 |
31113936 | XPO1 inhibitor KPT-330 synergizes with Bcl-xL inhibitor to induce cancer cell apoptosis by perturbing rRNA processing and Mcl-1 protein synthesis. | 2019 May 21 |
1 |
| 11 |
29928488 | Mechanisms for mTORC1 activation and synergistic induction of apoptosis by ruxolitinib and BH3 mimetics or autophagy inhibitors in JAK2-V617F-expressing leukemic cells including newly established PVTL-2. | 2018 Jun 1 |
2 |
| 12 |
26939706 | Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models. | 2016 May |
2 |